细胞免疫疗法对血液系统恶性肿瘤治疗作用的研究进展

Research Progress of Cell Immunotherapy in Treatment of Hematological Malignancies——Review

细胞免疫治疗将体外扩增的大量免疫效应细胞回输给患者,产生杀伤肿瘤细胞的作用,成为肿瘤治疗的一种重要手段,包括T细胞治疗、以树突状细胞为基础的细胞治疗、自然杀伤细胞治疗和γδT细胞治疗等。这些免疫细胞的制备及培养条件、抗肿瘤机制、作用的靶细胞等不尽相同且各有优缺点。临床研究显示,包括恶性血液病在内的多种肿瘤患者应用细胞免疫治疗后,生存期延长、生活质量改善且不良反应较少。本文就常见的不同种类细胞治疗的特点及在血液系统恶性肿瘤中的应用作一综述。

Cell immunotherapy, as an important mean of tumor therapy, infuses a large number of immune effector cells amplified in vitro to the patients, resulting in the anti-tumor effect. There have been a series techniques of cell immunotherapy, including T lymphocyte therapy, dendritic cell-based immune cell therapy, natural killer cell therapy, gamma delta T cell therapy and so on. The preparation and culture conditions, anti-tumor mechanism, target cells etc of these immune cells are not the same, the each with its advantages and disadvantages. Many clinical studies have showed that the patients with a variety of tumors including hematological malignancies, who adopted cell immuno-therapy, had the prolonged survival, an improved quality of life, and with the less adverse reactions. This review summarizes the available data on the characteristics of different cell immunotherapies and their application in hematological malignancies.